Role of Huachansu in Treating Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPase

Summary

Primary Outcome Measures: \- To compare the progression free survival(PFS) in patients with unresectable hepatocellular carcinoma(HCC) treated with transcatheter arterial chemoembolization(TACE) with or without Huachansu, and the correlation between PFS and expression of peripheral Na+/K+-ATPase α3 family. Secondary Outcome Measures: \- To compare the overall survival(OS), objective response rate(ORR), and side effects of treating HCC with TACE plus Huachansu or TACE alone. Exploratory Outcome Measures: \- To evaluate the correlation between prognosis and expression of peripheral Na+/K+-ATPase α3 family.

Timeline

Start

2012-07

Primary completion

2016-06

Completion

2016-06

Outcome

Met primary endpoint

paper PFS and OS were significantly better in the Huachansu-TACE group than in the TACE group (p=0.029 and p=0.025, respectively), PMID 37400162 ↗

Publications

• Gao H, He J, Cheng CS, Zhuang L, Chen H, Meng Z. Unresectable hepatocellular carcinoma: transarterial chemoembolisation plus Huachansu - a single-center randomised controlled trial. BMJ Support Palliat Care. 2023 Jul 3;14(e2):e003870. doi: 10.1136/spcare-2022-003870. Online ahead of print.

Drugs

Indications